STAT3 and cancer: Inhibiting IL-6/JAK/STAT3 signaling or STAT3 activity alone with antisense oligonucleotides, siRNA, or small-molecule inhibitors can dramatically sensitize cancer cells to treatment with EGFR inhibitors [212,214,217].